SML0189

Indinavir sulfate salt hydrate

≥98% (HPLC), powder, antiretroviral agent

• Sinónimos: 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate hydrate, Crixivan hydrate, L-735,524 hydrate, MK-639 hydrate
• Fórmula empírica (notación de Hill): C₃₆H₄₇N₅O₄·H₂SO₄ · xH₂O
• Peso molecular: 711.87 (anhydrous basis)
• Código UNSPSC: 51111800
• NACRES: NA.77

Propiedades

• product name: Indinavir sulfate salt hydrate, ≥98% (HPLC)
• Análisis: ≥98% (HPLC)
• formulario: powder
• condiciones de almacenamiento: desiccated
• color: white to tan
• solubilidad: H₂O: ≥15 mg/mL
• emisor: Merck & Co., Inc., Kenilworth, NJ, U.S.
• temp. de almacenamiento: 2-8°C

Descripción

Aplicación

Indinavir sulfate salt hydrate may be used in HIV-related cell signaling studies.

Acciones bioquímicas o fisiológicas

Indinavir sulfate is an antiviral HIV protease inhibitor.

Indinavir sulfate suppresses the replication of HIV and is an important component of antiretroviral therapy for initial treatment of HIV infection. It is known to cause renal and urologic toxicity.

Características y beneficios

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable